The Patent Trial and Appeal Board did not err in finding that certain claims of Slot Speaker Technologies, Inc.’s sound reproduction system patent were invalid as obvious in light of prior art, according to the U.S. Court of Appeal for the Federal Circuit. However, the Board erred in holding that a third claim was not…

Pharmaceuticals company Watson’s proposed generic version of competitor Shire’s brand-name mesalamine LIALDA® did not satisfy the requirements for a Markush group claimed by a Shire patent, the U.S. Court of Appeals for the Federal Circuit has held. A compound contained in the ANDA product—which was not present in the patent claim’s Markush group—structurally and functionally…

Two patents directed to a method for the electronic trading of stocks, bonds, futures, and options asserted by Trading Technologies International (TTI) against the CQG companies were not directed to an abstract idea and also recited an inventive concept, the U.S. Court of Appeals for the Federal Circuit has ruled. In affirming a federal district…

A federal district court erred in ruling that 34 claims of a patent on a system and method of using a graphical indicator were invalid as indefinite, the U.S. Court of Appeals for the Federal Circuit has ruled. Because a skilled artisan would understand, with reasonable certainty, the meaning of the term “visually negligible,” and…

In a unanimous decision, the Supreme Court reversed and remanded a Federal Circuit decision upholding a jury’s award of damages to Apple Inc. based on infringement of its design patents by Samsung Electronics, Co. Ltd. At issue was whether, in the case of a multicomponent product, the relevant “article of manufacture” must always be the…

The federal district court in Los Angeles did not err in granting default judgment and a permanent injunction to United Construction Products, Inc. dba Bison Innovative Products on its patent infringement and unfair competition claims against Tile Tech, Inc., the U.S. Court of Appeals for the Federal Circuit has ruled (Tile Tech, Inc. v. United…

Purchasers of AstraZeneca LP’s heartburn medication Nexium were not entitled to a new trial to their challenge of “reverse payment” agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. Court of Appeals in Boston has decided. The plaintiffs’ argument that the trial court improperly…

The Patent Trial and Appeal Board properly found during inter partes review (IPR) that two claims of a patent directed to a mechanism for controlling the operation of a downhole drill string were invalid as anticipated by a prior art reference, the U.S. Court of Appeals for the Federal Circuit has decided. The court rejected…

1. History One of the most precious achievements that Europe inherited from England is the so-called Rule of Law, dating back from the days of James I who ruled the union of the Scottish and English crowns from 1603 until his death in 1625. The key parts of this model is that laws are made…

Actavis Laboratories UT, Inc. was unable to show that patents licensed to Endo Pharmaceuticals Inc. covering its testosterone gel product Fortesta® were invalid as obvious in light of prior art, according to the U.S. Court of Appeals for the Federal Circuit. Therefore, a district court ruling finding that the patents were not obvious was affirmed…